Animal Placental Protein Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product Type (Extracts, Powders, Capsules/Tablets, Injections), By Application (Pharmaceuticals, Cosmetics and Personal Care Products, Nutraceuticals and Dietary Supplements, Research and Biotechnology), By Animal Source (Bovine, Porcine, Ovine, Equine, Others), By Distribution Channel (Direct Sales, Retail Sales, Online Retail), By Region and Competition 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 544.62 Million
CAGR (2026-2031)	5.26%
Fastest Growing Segment	Capsules/Tablets
Largest Market	North America
Market Size (2031)	USD 740.75 Million

Market Overview

The Global Animal Placental Protein Market will grow from USD 544.62 Million in 2025 to USD 740.75 Million by 2031 at a 5.26% CAGR. Animal placental protein is a bioactive ingredient extracted from the postpartum tissue of mammals such as swines, ovines, and equines, valued for its high concentration of growth factors, amino acids, and enzymes. The global market is primarily supported by the expanding cosmeceutical sector seeking potent anti-aging formulations and the increasing adoption of regenerative medicine therapies for tissue repair. Additionally, the rising consumer preference for nutrient-dense, organ-based nutritional supplements continues to bolster the commercial demand for these specialized protein fractions.

However, the industry faces significant impediments due to stringent regulatory protocols aimed at mitigating disease transmission risks and ensuring biological safety in animal by-product sourcing. According to the China Animal Agriculture Association, in 2024, the industry initiated a strategic reduction of the breeding sow herd by approximately 1 million head to address market oversupply, a development that directly constrains the raw material supply chain for porcine placental protein production. This fluctuation in livestock availability presents a notable challenge to maintaining consistent production volumes for manufacturers reliant on porcine sources.

Key Market Drivers

The surging demand for anti-aging and skin rejuvenation cosmetic formulations is acting as a primary catalyst for the global animal placental protein market. As consumers increasingly prioritize non-invasive aesthetic enhancements, the industry is witnessing a parallel rise in the utilization of bioactive ingredients capable of accelerating post-procedure recovery and stimulating collagen synthesis. This trend is substantiated by data from the International Society of Aesthetic Plastic Surgery, which revealed in June 2024 that 19.1 million non-surgical procedures were performed globally in the preceding year, creating a robust commercial avenue for placenta-enriched aftercare products. Manufacturers are capitalizing on this shift by integrating protein fractions into cosmeceuticals designed to mimic the regenerative effects of clinical treatments, thereby driving high-volume procurement of raw extracts.

Concurrently, the market is being propelled by expanding applications in regenerative medicine and wound care therapeutics, where animal-derived scaffolds are proving essential for tissue engineering. Recent clinical advancements have validated the efficacy of these biological matrices in treating complex skin injuries, further legitimizing their medical adoption. For instance, a real-world study published in Cureus in December 2024 demonstrated that 53% of hard-to-heal wounds managed with a porcine placental extracellular matrix achieved complete closure, underscoring the material's potent therapeutic potential. To support such medical-grade applications, the supply chain for specialized animal by-products remains active; according to Deer Industry New Zealand, in the year ending September 2024, the export volume of deer co-products, a key category for bioactive extraction, reached 4,944 tonnes. This consistent availability of high-quality raw material is pivotal for meeting the stringent requirements of the growing therapeutic sector.

Download Free Sample Report

Key Market Challenges

The primary impediment to market expansion is the instability of raw material supply chains resulting from fluctuations in global livestock inventories. Since the production of animal placental protein relies entirely on the collection of postpartum tissue, the industry is vulnerable to any contraction in swine, ovine, or equine herd sizes. When breeding populations decrease due to disease outbreaks, economic pressures, or regulatory herd management, the volume of extractable biological material diminishes. This dependency creates significant production bottlenecks, preventing manufacturers from maintaining the consistent inventory levels required to meet rising commercial demand.

According to the American Sheep Industry Association, in 2024, the total inventory of sheep and lambs in the United States decreased by 2 percent, reflecting a continued contraction in the availability of ovine sources. This reduction in the biological base directly impacts the supply capacity for ovine-derived ingredients. Consequently, manufacturers face increased competition for limited resources and higher procurement costs, which restricts their ability to scale operations and hampers the overall growth trajectory of the placental protein sector.

Key Market Trends

The distinct surge in the utilization of porcine-derived placental protein within Korean cosmetic formulations is reshaping the market, driven by the ingredient’s high histocompatibility with human skin and the aggressive global expansion of K-Beauty brands. As manufacturers reformulate sheet masks and ampoules to capitalize on this biological affinity, the export volume of these finished goods has escalated, necessitating higher procurement volumes of porcine raw material to meet international orders. This trend is substantiated by the sector's robust trade performance; according to the Korea Customs Service, January 2025, skincare exports to the United States rose more than threefold to reach $815.1 million in 2024, underscoring the significant commercial channel through which these placenta-enriched products are now penetrating Western markets.

Simultaneously, the market is witnessing the rapid emergence of Halal-certified ovine placenta extracts designed to secure access to strictly regulated consumer bases in Southeast Asia and the Middle East. Producers are increasingly substituting porcine ingredients with sheep-derived alternatives to ensure religious compliance, a strategic shift supported by record-breaking availability of biological inputs from major export hubs like Australia. This supply-side capacity is critical for scaling production to meet the Halal mandate; according to Meat & Livestock Australia, September 2024, in the 'Sheep Industry Projections' report, the national sheep flock reached 79.1 million head in June 2024, the largest figure since 2007, providing a stable and traceable raw material foundation for these specialized compliant formulations.

Segmental Insights

The Capsules and Tablets segment is currently identified as the fastest-growing category within the Global Animal Placental Protein Market. This accelerated expansion is primarily driven by the increasing consumer preference for convenient, taste-masked dosage forms that effectively overcome the palatability issues often associated with liquid placental extracts. The rising popularity of "beauty from within" dietary supplements further fuels this trend, as solid oral forms allow for precise dosing and easy integration into daily wellness routines. Moreover, compliance with rigorous quality standards, such as Current Good Manufacturing Practices (cGMP), ensures product safety and stability, thereby strengthening consumer confidence and fostering widespread market adoption.

Regional Insights

North America leads the Global Animal Placental Protein Market, supported by a robust healthcare infrastructure and extensive investment in biomedical research. The region benefits from substantial demand within the pharmaceutical sector, where placental extracts are utilized for wound healing and regenerative therapies. Furthermore, the thriving personal care industry drives market activity, as consumers with higher disposable incomes prioritize premium anti-aging formulations rich in bioactive ingredients. This market position is strengthened by the presence of major manufacturers and rigorous quality standards that facilitate the widespread commercialization of placental protein products across the United States and Canada.

Recent Developments

• In November 2025, Japan Bio Products Co., Ltd. expanded its global distribution capabilities by opening the "JBP Global One-stop Online Shop." This new direct-to-consumer platform was established to provide international customers with easier access to the company's range of placenta-based health and beauty products, including its well-known supplements and cosmetics. The launch marked a strategic effort by the company to combat unauthorized distributors and ensure product authenticity for its global client base. This initiative reflected the company's commitment to strengthening its brand presence and supply chain integrity in the competitive global market.
• In May 2024, Active Iida Co., Ltd. launched a new skincare product under its "&NAGOMI" brand featuring premium horse placenta extract. The newly released "Horse Oil Cream Premium" was formulated with high-purity placenta extract derived from Hokkaido Thoroughbred horses, designed to revitalize the skin by delivering essential amino acids, vitamins, and growth factors. The product launch highlighted the company's focus on upcycled cosmetic ingredients, utilizing resources from the horse meat industry that would otherwise be discarded. This development underscored the growing consumer demand for natural, sustainable, and high-performance animal-derived skincare solutions.
• In February 2024, MBI announced a strategic alliance with RE Biotech, a subsidiary of Japan Bio Products Co., Ltd., to advance the development of cosmetic medical materials. Through this collaboration, Japan Bio Products, a global leader in placental products, granted MBI authorization to co-develop and manufacture advanced materials utilizing its proprietary placenta extracts. The partnership aimed to leverage RE Biotech’s expertise in collagen and stem cell-derived technologies to create innovative aesthetic solutions. This move was described as a significant step in deepening the companies' presence in the international beauty and medical aesthetics market.
• In January 2024, a study supported by Daehan Chemtech Co., Ltd. was published detailing the anti-aging properties of porcine placenta peptide (PPP). The research, which appeared in a scientific journal, demonstrated that oral administration of PPP effectively inhibited UVB-induced skin wrinkle formation and dehydration in in vivo models. The findings indicated that the peptide suppressed specific signaling pathways associated with skin damage while upregulating collagen production and antioxidant enzyme levels. This breakthrough highlighted the potential of porcine placental peptides as a functional ingredient for developing effective anti-aging skincare and health food products.

Key Market Players

• Merck KGaA
• Biotain Pharma Co., Ltd.
• New Zealand Health Food Company Limited
• XABC Biotech Co., Ltd.
• Chaitanya Biologicals Pvt. Ltd.
• Serolab SA
• Auckland BioSciences Limited
• ANZCO Foods Limited
• Biocontinental Co., Ltd.

By Product Type	By Application	By Animal Source	By Distribution Channel	By Region
Extracts Powders Capsules/Tablets Injections	Pharmaceuticals Cosmetics and Personal Care Products Nutraceuticals and Dietary Supplements Research and Biotechnology	Bovine Porcine Ovine Equine Others	Direct Sales Retail Sales Online Retail	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Animal Placental Protein Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Animal Placental Protein Market, By Product Type:

• Extracts
• Powders
• Capsules/Tablets
• Injections

• Animal Placental Protein Market, By Application:

• Pharmaceuticals
• Cosmetics and Personal Care Products
• Nutraceuticals and Dietary Supplements
• Research and Biotechnology

• Animal Placental Protein Market, By Animal Source:

• Bovine
• Porcine
• Ovine
• Equine
• Others

• Animal Placental Protein Market, By Distribution Channel:

• Direct Sales
• Retail Sales
• Online Retail

• Animal Placental Protein Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE